New mRNA vaccine targets RSV in first human trial
NCT ID NCT06573281
First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This early-stage trial is testing several doses of an experimental mRNA vaccine against RSV in 213 healthy adults aged 18-45. The goal is to check the vaccine's safety and how well it triggers an immune response. Participants receive two shots, and researchers monitor for side effects and measure antibody levels.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
mRNA-based RSV vaccine
What this could lead to
If successful, this could lead to a new vaccine to protect against RSV, a common respiratory virus that can be serious for infants and older adults.
What could go wrong
This is an early Phase 1 trial with only 213 healthy adults, so safety and immune response are still being tested. It may not work in larger, more diverse populations or against different RSV strains.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RESPIRATORY SYNCYTIAL VIRUS INFECTIONS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
GSK Investigational Site
Rolling Hills Estates, California, 90274, United States
-
GSK Investigational Site
Atlanta, Georgia, 30281, United States
-
GSK Investigational Site
Lenexa, Kansas, 66219, United States
-
GSK Investigational Site
Omaha, Nebraska, 68134, United States
-
GSK Investigational Site
Rochester, New York, 14609, United States
-
GSK Investigational Site
Camberwell, Victoria, 3124, Australia
-
GSK Investigational Site
Madrid, 28006, Spain
-
GSK Investigational Site
Madrid, 28046, Spain
-
GSK Investigational Site
Madrid, 28222, Spain